InvestorsHub Logo
Post# of 4981116
Next 10
Followers 796
Posts 118388
Boards Moderated 0
Alias Born 11/20/2004

Re: None

Tuesday, 06/26/2007 8:51:05 AM

Tuesday, June 26, 2007 8:51:05 AM

Post# of 4981116
TGTI news! this one is primed for higher pps
enthGate Acquires Two Additional Technology Licenses in Support of Their Melanoma Diagnostics and Prevention Initiatives
Jun 26, 2007 8:00:00 AM
2007 PrimeNewswire, Inc.
RESTON, Va., June 26, 2007 (PRIME NEWSWIRE) -- TenthGate International, Inc., www.TenthGate.biz (Pink Sheets:TGTI), ("TenthGate"), an innovative medical holding company focusing on healthcare related life-changing technologies, announced the addition of the fourth and fifth technology licenses by their wholly owned subsidiary TenthGate Incorporated through Science & Technology Corporation at the University of New Mexico (STC.UNM) http://stc.unm.edu/ . The titles of the two new technology licenses acquired are:

"In vivo determination of melanocyte protection ability of sunscreens using reactive melanin radical formation as a relevant endpoint"

"Post Exposure Prophylaxis of Melanoma Causation"

The three previous related technologies licensed by TenthGate from STC.UNM include:

"Molecular imaging of melanoma"

"Molecular assay of the UVA protective efficacy of sunscreens"

"Detecting metastatic melanoma in sentinel lymph nodes by EPR (Electron Paramagnetic Resonance)"

Except for lung cancer in women, the incidence of melanoma is growing faster than any cancer in the United States. It has become one of the more common cancers among young adults.

Per Tim Novak, Chairman and Chief Executive Officer of TenthGate; "We continue to expand the scope of our intellectual properties surrounding this "life-changing" technology developed at the University of New Mexico School of Pharmacy by Dr. Graham Timmins. The focus is on understanding the causation factors of melanoma skin cancer, using Electron Paramagnetic Resonance (EPR) diagnostics at the melanin free radical level to help guide us to specific prevention strategies. Initial benefits will be directed at product retailers and manufacturers who can provide a more exact description of the protective effectiveness of their sunscreens and other cosmetic products, allowing consumers to make better informed decisions on responsible sun exposure protective measures. We have made application and are pending trademark approval for 'MPF' for 'Melanocyte Protective Factor', which will be used to quantitatively describe this new protective efficacy scale in a standardize fashion."
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.